ArticleCureus2025
Outcomes of Combined Therapy With Focal Laser and Intravitreal Bevacizumab for Retinal Arterial Macroaneurysm: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal arterial macroaneurysms (RAMAs) are uncommon vascular abnormalities that can lead to significant visual impairment if left untreated. While various management strategies exist, there is no universally accepted standard of care, and treatment is often guided by the severity of associated hemorrhage and fluid accumulation. The purpose of this case series is to evaluate and discuss the management and the use of combination therapy in the form of focal laser (FL) treatment and intravitreal anti-vascular endothelial growth factor (VEGF) injections in patients with retinal arterial macroaneurysms (RAMAs). A retrospective chart review was conducted on the patients, including their clinical histories, comorbidities, age, and treatment methods. Baseline and posttreatment vision were obtained, and a detailed literature review was conducted emphasizing treatment and outcomes. All three patients had a complete resolution of the subretinal and intraretinal fluid associated with the RAMA with combination therapy with considerable improvement in vision. The average improvement in visual acuity (VA) across the three cases was 0.55 logarithm of the minimum angle of resolution (logMAR). The central retinal thickness (CRT) decreased on average by 275.7 µm at the three-month mark. Combination therapy with anti-VEGF and focal laser appears to be an effective and definitive treatment for retinal arterial macroaneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.